COMING SOON: Food products that contain higher levels of phytosterols for reduced cholesterol, crops with higher levels of carotenoids for increased vitamin A, potato loaded with antioxidants, low-linolenic soybean, and high-lysine corn.

These may be farfetched but the possibilities are endless. Thanks to genetic engineering, the crops of the future will no longer be just dreams but realities. Already, the world has seen eggplant and corn that defy pests, vitamin A-rich rice, herbicide tolerant soybean, virus resistant papaya, and high laureate canola.

They are called genetically modified (GM) crops, which are products of biotechnology, a "technique that makes use of organism (or parts of it) to make or modify products, to improve plants or animals, or to develop microorganisms for specific purposes."

GM crops are made through a process called genetic engineering. Dr. Antonio Alfonso, a plant breeder at the Philippine Rice Research Institute (PhilRice) and the Crops Biotechnology Center director said genetic engineering is employed because of the following reasons: the trait is not present in the germplasm of the plant; the trait is very difficult to incorporate using conventional breeding methods; and it would take a very long time to introduce and/or improve such trait in the crop through conventional breeding.

In 1994, Calgene's delayed-ripening tomato became the first GM food crop to be produced and consumed in an industrialized country. Other GM crops -- corn, soybean, cotton, canola, and eggplant -- followed. These are called "first generation" crops which have proven their ability to lower farm-level production costs.

Now, research is focused on "second generation" GM crops that will feature increased nutritional and/or industrial traits. These crops will have more direct benefits to consumers. Examples include: potatoes with higher starch content and inulin; edible vaccines in corn, banana, and potatoes; corn varieties with low phytic acid and increased essential amino acids; healthier oils from soybean and canola; and allergen-free nuts.

These are called functional foods. It is defined as "foods or dietary components that claim to provide health benefits aside from basic nutrition." These foods contain biologically active substances such as antioxidants that may lower the risks from certain diseases associated with aging.

"Diet and health are closely related," explains the International Service for the Acquisition of Agri-biotech Applications (ISAAA). "Thus crops are now being enhanced through biotechnology to increase levels of important biologically active substances for improved nutrition, to increase body's resistance to illnesses, and to remove undesirable food components."

Linoleic acid (LA), alpha-linolenic acid (ALA), and polyunsaturated fatty acids (PUFAs) are some of the essential fatty acids. These are considered essential because they cannot be synthesized by the human body. A large number of scientific research studies suggest that higher dietary essential fatty acid intakes are associated with reductions in cardiovascular disease risk.

The main food sources of the long-chain Omega-3 fatty acids are fish. Plants lack the enzymes to make long-chain fatty acids needed by human beings. Scientists at the University of Bristol modified Arabidopsis thaliana to produce long-chain PUFAs.

Go here to see the original:
Functional crops are coming

Recommendation and review posted by Bethany Smith

Dr. Thomas Merritt - God in Genetics
Dr. Thomas Merritt answers the question, "Are we finding proof today that everything religion has been teaching us is slowly making more sense with the advancement of genetics to explain to...

By: LetsTalkScience

See the original post here:
Dr. Thomas Merritt - God in Genetics - Video

Recommendation and review posted by Bethany Smith

Stacy Alaimo Chapter Six "Genetics, Agency, and Ethics"

By: Angela Bennett Segler

Originally posted here:
Stacy Alaimo Chapter Six "Genetics, Agency, and Ethics" - Video

Recommendation and review posted by Bethany Smith

2014 Spring Trials: HEM Genetics, Limbo Petunia
Description.

By: SpringTrials.org

Originally posted here:
2014 Spring Trials: HEM Genetics, Limbo Petunia - Video

Recommendation and review posted by Bethany Smith

Minecraft: Attack of the B-Team! Unadvanced Genetics - E33
Mark of the Old Ones on Kickstarter! http://kck.st/1e5v1wA SKYZM ONLINE Twitter http://www.twitter.com/skyzm Twitch https://www.twitch.tv/skyzmLP Facebook https://www.facebook.com/sky...

By: skyzm

Read this article:
Minecraft: Attack of the B-Team! Unadvanced Genetics - E33 - Video

Recommendation and review posted by Bethany Smith

Human embryonic stem cells can become any cell in the body. AFP FILE PHOTO

MANILA, Philippines Health authorities warned the public anew on Saturday about health facilities and medical practitioners offering unauthorized stem cell therapy and products.

In an advisory, the Food and Drug Administration said that to date, not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use, or general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said, reminding hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs, the advisory added.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care procedures.

If health institutions are doing these three procedures, they can continue doing them because those are allowed. Go said, adding that the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, has yet to be proven.

Go noted that while many spa centers and salons are advertising stem cell therapy and products, none of them has the approval of the health agency.

As of now we have not accredited any health facility offering stem cell therapy yet, Go said.

Several facilities had applied for accreditation but Go said many of these were asked to correct their deficiencies.

Read the original here:
Public warned of fly-by-night stem cell procedures, products

Recommendation and review posted by simmons

Skin cells from infertile men can be turned into the precursors of sperm cells in a lab, according to a new study.

The findings raise the possibility of one day making sperm from the skin cells of men with fertility problems, the researchers said. However, much more research is needed to determine if this is possible and whether it is safe.

In the new study, researchers first transformed the men's skin cells into stem cells, then implanted the cells into the testes of mice where they formed sperm precursor cells. However, one safety issue is that some of the stem cells formed tumors in the mice, said study researcher Renee Reijo Pera, who conducted the work while at Stanford University, and is now a professor of cell biology and neurosciences at Montana State University.

To conduct the study, Pera and colleagues took skin samples from three infertile men, and two fertile men. The infertile men had a genetic mutation in a region of the genome called AZF1 that prevented them from making mature sperm, a condition called azoospermia. [Sexy Swimmers: 7 Facts About Sperm]

The researchers used the skin cells to produce what are called induced pluripotent stem cells (iPS cells), which have the ability to become nearly any tissue type in the body. These iPS cells were then implanted into the testes of mice, where they turned into germ cells, which normally give rise to sperm in males.

However, in the study, the germ cells did not go on to form mature sperm in the mice, likely because of evolutionary differences between humans and mice that blocked the production of such mature cells, Pera said.

The stem cells from fertile men were much better at generating germ cells than those from infertile men. Still, the fact that the infertile men's stem cells produced germ cells at all was surprising, because men with the AZF1 mutation often have no germ cells, Pera said.

The new findings suggest that these infertile men do in fact have the potential to produce germ cells, but the germ cells are lost over time, Pera said. If that's true, young boys with this mutation might be able to preserve their germ cells for the future by collecting and freezing samples of testes tissue, Pera said.

The mouse model used in the study will help researchers better understand the earliest stages of sperm development, Pera said. For example, the cells of human embryo "decide" whether they are going to be germ cells at day 12 after conception, she said. "We've developed a way to study the earliest steps," which take place in the fetus, Pera said.

Previously, the same group of researchers created germ cells from human embryonic stem cells. And last year, experiments in mice showed that skin cells of the animals can be turned into stem cells, which can then be turned into germ cells. When researchers implanted these germ cells in sterile mice, the mice became fertile.

Originally posted here:
Skin cells turned into sperm

Recommendation and review posted by Bethany Smith

May 2, 2014 7:02 pm by Stephanie Baum | 0 Comments MedCity News

In the latest stem cell innovation, a group of researchers from Stanford University successfully converted skin cells to stem cells to sperm cells, raising new questions about a potential path to treat infertility. The study was published in Cell Report.

The research used skin samples from five men with a genetic mutation calledazoospermia a genetic mutation that prevented them from making mature sperm.

According to a description of the study on NPRs website, researchers took skin cells from infertile men and transformed them into pluripotent stem cells, which can be converted into any cell in the body. The cells were inserted in mice testes and became immature human sperm cells.

The research is certainly at the early stage and experts caution it will take a lot more research to develop healthy sperm but it is already drawing mixed responses from the research world. Although its been called provocative, Dartmouth bioethicist Ronald Green got particularly dark and called attention to the downside. He speculated that it could lead to thefts of tissue samples or hair from the dead to recreate the dearly departed.

Get our daily newsletter or follow us.

Please enter your email below:

Excerpt from:
Stem cell innovation study converts skin cells to sperm cells in potential infertility treatment

Recommendation and review posted by Bethany Smith

By Estel Grace Masangkay

An independent group of scientists led by experts at the New York Stem Cell Foundation Research Institute (NYSCF) reported that they have manufactured the first disease-specific line of embryonic stem cells made with a patients DNA. The achievement is heralded as a major breakthrough in the regenerative medicine field.

This is also the first time cloning technologies have been utilized to generate genetically matched stem cells. The team used somatic cell nuclear transfer to successfully clone a skin cell from a 32 year old female patient with Type 1 diabetes. The cells were transformed into insulin-producing cells similar to lost beta cells in diabetes, which could provide better treatment or even a cure for T1D.

Susan Solomon, CEO and co-founder of NYSCF, says she is excited about the successful production of patient-specific stem cells using somatic cell nuclear transfer (SCNT). CEO Solomon said she became involved with medical research when her son was diagnosed with T1D.

Dr. Egli, scientist from the New York Stem Cell Foundation Research Institute and who led the research, said, From the start, the goal of this work has been to make patient-specific stem cells from an adult human subject with type-1 diabetes that can give rise to the cells lost in the disease. By reprograming cells to a pluripotent state and making beta cells, we are now one step closer to being able to treat diabetic patients with their own insulin-producing cells.

The scientists analyzed factors that affect stem-cell derivation after SCNT. They added histone deacetylase inhibitors and protocol for human oocyte activation, which were crucial in delivering them to the stage at which embryonic stem cells can be properly derived. The beta cells produced from the patients own skin cells are autologous and match the patients DNA. Further research is underway at NYSCF and other institutions for the development of strategies to protect existing and therapeutic beta cells from attacks of the immune system.

The research teams work appeared in the journal Nature.

See the original post:
Scientists Produce Personalized Stem Cells For Specific Diseases

Recommendation and review posted by Bethany Smith

(PRWEB) May 02, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download Free PDF Download @ http://www.marketsandmarkets.com/pdfdownload.asp?id=48

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

A number of factors such as the increasing funding from various government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are stimulating the research activities for stem cell therapies. Developing markets, emergence of induced pluripotent stem (iPS) cells as an alternative to embryonic stem cells (ESCs), and evolution of new stem cell therapies represent high growth opportunities for market players.

In 2015, North America will hold the largest share of the global stem cell therapy market. This large share is primarily attributed to the extensive government funding and increasing fast-track approval for stem cell therapeutics by the FDA. Moreover, development of advanced genomic methods for stem cell analysis and high number of ongoing research activities are further fueling the growth of the stem cell therapy market in North America. However, the Asia-Pacific stem cell therapy market is expected to grow at the highest CAGR in the forecast period, owing to factors such as increasing regulatory support through favorable government policies, strong product pipelines, and increasing licensing activities in this region.

Read more:
Stem Cell Therapy Market (Autologous & Allogeneic) Worth $330 Million in 2020 - New Report by MarketsandMarkets

Recommendation and review posted by Bethany Smith

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

See the original post here:
Stem Therapy May Improve Survival of Heart Patients

Recommendation and review posted by Bethany Smith

New York, NY (PRWEB) May 02, 2014

Stem Cell Institute is releasing additional tickets for its Adult Stem Cell Therapy Clinical Trials seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

After booking its original meeting room beyond capacity, the Stem Cell Institute has reserved a larger room to accommodate additional attendees. The seminar will now take place in the Beekman Room, 2nd Floor, East Corridor of the New York Hilton Midtown.

Those interested in attending are encouraged to register promptly. Only 75 additional seats are available.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special guest speaker:

See original here:
Additional Tickets Released for Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New ...

Recommendation and review posted by Bethany Smith

In a new study published today in Cell Reports, scientists at the Fred Hutchinson Cancer Research Center demonstrate that mice lacking one copy of a gene called CTCF have abnormal DNA methylation and are markedly predisposed to cancer.

CTCF is a very well-studied DNA binding protein that exerts a major influence on the architecture of the human genome, but had not been previously linked to cancer. Over 30 years ago, frequent loss of one copy of chromosome 16 was first reported in breast cancer but the gene or genes responsible remained to be identified. Dr. Gala Filippova, staff scientist at Fred Hutch and co-author of the study, originally cloned the human CTCF gene and mapped it to chromosome 16, within the same region that is frequently lost in human cancers. That same year, Dr. Chris Kemp of the Human Biology Division at Fred Hutch, co-authored a paper demonstrating that, in contrast to the predominant "two hit" theory on tumor suppressor genes, it was not necessary to lose both copies, one hit was enough. However, CTCF was ruled out as a candidate breast cancer gene on chromosome 16 simply because it did not conform to the "two hit" model.

"In this current study we explored whether loss of just one copy of the CTCF gene could trigger epigenetic changes and predispose to tumor development," said Dr. Filippova of Fred Hutch. The study demonstrates that indeed, loss of one copy of CTCF caused large scale epigenetic changes and greatly enhanced tumor formation in multiple tissues. In addition, recent large scale analysis of the human cancer genome revealed that deletions or mutations in CTCF are one of the most common events in breast, endometrial, and other human cancers.

Collectively, these findings indicate that CTCF is major tumor suppressor gene in human cancer and highlights the power of the mouse models to prove that a candidate gene has a function in cancer. These results have implications for understanding the origin of DNA methylation alterations in cancer and suggest that epigenetic instability may both precede and accelerate the emergence of cancer.

"This answers a 30 year riddle in cancer research," said Dr. Kemp. "And it shows once again, as we first showed in 1998, that one hit is enough."

Story Source:

The above story is based on materials provided by Fred Hutchinson Cancer Research Center. Note: Materials may be edited for content and length.

Originally posted here:
30-year puzzle in breast cancer solved

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

1-May-2014

Contact: Michael Nank mnank@fredhutch.org 206-667-2210 Fred Hutchinson Cancer Research Center

In a new study published today in Cell Reports, scientists at the Fred Hutchinson Cancer Research Center demonstrate that mice lacking one copy of a gene called CTCF have abnormal DNA methylation and are markedly predisposed to cancer. CTCF is a very well-studied DNA binding protein that exerts a major influence on the architecture of the human genome, but had not been previously linked to cancer. Over 30 years ago, frequent loss of one copy of chromosome 16 was first reported in breast cancer but the gene or genes responsible remained to be identified. Dr. Gala Filippova, staff scientist at Fred Hutch and co-author of the study, originally cloned the human CTCF gene and mapped it to chromosome 16, within the same region that is frequently lost in human cancers. That same year, Dr. Chris Kemp of the Human Biology Division at Fred Hutch, co-authored a paper demonstrating that, in contrast to the predominant "two hit" theory on tumor suppressor genes, it was not necessary to lose both copies, one hit was enough. However, CTCF was ruled out as a candidate breast cancer gene on chromosome 16 simply because it did not conform to the "two hit" model.

"In this current study we explored whether loss of just one copy of the CTCF gene could trigger epigenetic changes and predispose to tumor development," said Dr. Filippova of Fred Hutch. The study demonstrates that indeed, loss of one copy of CTCF caused large scale epigenetic changes and greatly enhanced tumor formation in multiple tissues. In addition, recent large scale analysis of the human cancer genome revealed that deletions or mutations in CTCF are one of the most common events in breast, endometrial, and other human cancers.

Collectively, these findings indicate that CTCF is major tumor suppressor gene in human cancer and highlights the power of the mouse models to prove that a candidate gene has a function in cancer. These results have implications for understanding the origin of DNA methylation alterations in cancer and suggest that epigenetic instability may both precede and accelerate the emergence of cancer.

"This answers a 30 year riddle in cancer research", said Dr. Kemp. "And it shows once again, as we first showed in 1998, that one hit is enough".

###

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit http://www.fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

Contact

Link:
A 30-year puzzle in breast cancer is solved

Recommendation and review posted by Bethany Smith

Dartmouth Institute for Quantitative Biomedical Sciences (iQBS) researchers developed a new gene expression analysis approach for identifying cancer genes. The paper entitled, "How to get the most from microarray data: advice from reverse genomics," was published online March 21, 2014 in BMC Genomics. The study results challenge the current paradigm of microarray data analysis and suggest that the new method may improve identification of cancer-associated genes.

Typical microarray-based gene expression analyses compare gene expression in adjacent normal and cancerous tissues. In these analyses, genes with strong statistical differences in expression are identified. However, many genes are aberrantly expressed in tumors as a byproduct of tumorigenesis. These "passenger" genes are differentially expressed between normal and tumor tissues, but they are not "drivers" of tumorigenesis. Therefore, better analytical approaches that enrich the list of candidate genes with authentic cancer-associated "driver" genes are needed.

Lead authors of the study, Ivan P. Gorlov, Ph.D., Associate Professor of Community and Family Medicine and Christopher Amos, Ph.D., Professor of Community and Family Medicine and Director of the Center for Genomic Medicine described a new method to analyze microarray data. The research team demonstrated that ranking genes based on inter-tumor variation in gene expression outperforms traditional analytical approaches. The results were consistent across 4 major cancer types: breast, colorectal, lung, and prostate cancer.

The team used text-mining to identify genes known to be associated with breast, colorectal, lung, and prostate cancers. Then, they estimated enrichment factors by determining how frequently those known cancer-associated genes occurred among the top gene candidates identified by different analysis methods. The enrichment factor described how frequently cancer associated genes were identified compared to the frequency of identification that one could expect by pure chance. Across all four cancer types, the new method of selecting candidate genes based on inter-tumor variation in gene expression outperformed the other methods, including the standard method of comparing mean expression in adjacent normal and tumor tissues. Dr. Gorlov and colleagues also used this approach to identify novel cancer-associated genes.

The authors cite tumor heterogeneity as the most likely reason for the success of their variance-based approach. The method is based on the knowledge that different tumors can be driven by different subsets of cancer genes. By identifying genes with high variation in expression between tumors, the method preferentially identifies genes specifically associated with cancer. This same feature, tumor heterogeneity, may reduce the ability to identify critical gene expression changes when comparing mean gene expression in adjacent tumor and normal tissues, as tumors of the same type may have different sets of genes differentially expressed.

The results of the study challenge the model that comparing mean gene expression in adjacent normal and cancer tissues is the best approach to identifying cancer-associated genes. Indeed, the team identified high variation in adjacent "normal" tissue samples, which are typically used as control samples for comparison in analyses based on mean gene expression. The study suggests that methods based on variance may help get the most from existing and future global gene expression studies.

Story Source:

The above story is based on materials provided by The Geisel School of Medicine at Dartmouth. Note: Materials may be edited for content and length.

Read more from the original source:
Novel analyses improve identification of cancer-associated genes from microarray data

Recommendation and review posted by Bethany Smith

Korey Fung Ethics of Genetic Engineering Designer Babies Reproductive Revolution
Student Korey Fung presents "Ethics of Genetic Engineering: Designer Babies and the Reproductive Revolution" on April 8, 2014 in the Technology and Future of...

By: Kim Solez

Here is the original post:
Korey Fung Ethics of Genetic Engineering Designer Babies Reproductive Revolution - Video

Recommendation and review posted by Bethany Smith

No to Genetic Engineering | People and Politics
Genetic engineering is banned in berlingen by Lake Constance. The town in Baden-Wrttemberg, a state ruled by a coalition of the Green party and the Social ...

By: DW (English)

Here is the original post:
No to Genetic Engineering | People and Politics - Video

Recommendation and review posted by Bethany Smith

April Flowers for redOrbit.com Your Universe Online

A new study, from the Stanford University School of Medicine and Montana State University, demonstrates that, when implanted into the reproductive system of a mouse model, stem cells created from adult, infertile men will yield primordial germ cells. Primordial germ cells normally become sperm cells.

The findings, published in Cell Reports, help to further our understanding of a genetic cause of male infertility and basic sperm biology. The research team says that their approach holds considerable potential for clinical applications.

All of the infertile male participants suffer from a genetic mutation that prevents their bodies from producing mature sperm. The study suggests that the men with this condition called azoospermia might have produced germ cells at some point in their early lives, but these cells were lost as the men matured to adulthood.

Our results are the first to offer an experimental model to study sperm development, said Renee Reijo Pera of the Institute for Stem Cell Biology & Regenerative Medicine and Montana State University. Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm, she added. Considerable study to ensure safety and practicality is needed, however, before reaching that point.

Infertility is a fairly common problem, affecting between 10 and 15 percent of couples in the US. The researchers say that many men are affected by genetic causes of infertility, most commonly due to the spontaneous loss of key genes on the Y sex chromosome. Until now, the causes of infertility at the molecular level have not been clear.

The fact that the research team was able to create primordial germ cells from the infertile men is very promising, but they note that these stem cells created far fewer of these sperm progenitors than the stem cells of men without the genetic mutations. They are sure, however, that this research provides a much needed model to study the earliest steps of human reproduction.

We saw better germ-cell differentiation in this transplantation model than weve ever seen, said Reijo Pera, former director of Stanfords Center for Human Embryonic Stem Cell Research and Education. We were amazed by the efficiency. Our dream is to use this model to make a genetic map of human germ-cell differentiation, including some of the very earliest stages.

Humans share many cellular and physiological processes with common laboratory animals such as mice or fruit flies. In reproduction, however, there are significant variances, making it challenging to recreate the human reproductive processes in a laboratory setting. In addition, many crucial steps, such as the development and migration of primordial germ cells to the gonads,occur in the relatively short first days or weeks after conception.

See the rest here:
Stem Cells Of Infertile Men Used To Create Preliminary Sperm Cells

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 18
VampireClan #VampireClan4Life.

By: vampiregirl101101101

See more here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 18 - Video

Recommendation and review posted by Bethany Smith

Savior - a Gripping Genetics Thriller
Buy the e-book ($4): http://bookstore.xlibris.com/Products/SKU-0119138003/Savior.aspx or Amazon Kindle ($4): http://www.amazon.com/Savior-Frank-Camelio-ebook/dp/B009GDHTUQ/ref=sr_1_1?ie=UTF8 qid=13...

By: Frank Camelio

Read the original post:
Savior - a Gripping Genetics Thriller - Video

Recommendation and review posted by Bethany Smith

My Genetics
We all have a gift I challenge you to find yours and make the best of it. For more info go to: http://www.levronereport.com Peace Kevin.

By: levrone2000

Read the original here:
My Genetics - Video

Recommendation and review posted by Bethany Smith

The Sims 3 Perfect Genetics Challenge (Part 2) HELLO LOVELY!
OPEN FOR IMPORTANT LINKS AND INFO Like/Follow me on: ONLINE STORE: http://jessamica92.spreadshirt.com/ SECOND CHANNEL: http://www.youtube.com/user/JessaGames WEBSITE: http://www.jessamica...

By: jessamica92

Continued here:
The Sims 3 Perfect Genetics Challenge (Part 2) HELLO LOVELY! - Video

Recommendation and review posted by Bethany Smith

Retrovirus in Gene Therapy
A video created for gene therapy (SQG 4143-01). Lecturer: Dr. Salehhuddin Hamdan Students: (1) Tang Jiaa Earn (AQ100082) (2) Phang Shi YI (AQ100073)

By: Phang n Tang

See the rest here:
Retrovirus in Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Gene therapy for haemophilia - Professor Amit Nathwani
A Medicine for Members talk given on 22 April 2014 at the Royal Free Hospital by Professor Amit Nathwani.

By: Royal Free London NHS Foundation Trust

Here is the original post:
Gene therapy for haemophilia - Professor Amit Nathwani - Video

Recommendation and review posted by Bethany Smith

Cochlear Implant Gets an Upgrade with Gene Therapy
Cochlear Implant Gets an Upgrade with Gene Therapy This is a video of 3-D confocal imaging showing the cells secreting the neurotrophin (cyan) and the regene...

By: Stefano Di Criscio

The rest is here:
Cochlear Implant Gets an Upgrade with Gene Therapy - Video

Recommendation and review posted by Bethany Smith